Sorafenib Plus Toripalimab for Unresectable HCC With Portal Vein Tumor Thrombus
NCT04069949
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
UNKNOWN
Status
39
Enrollment
OTHER
Sponsor class
Conditions
Unresectable Hepatocellular Cancer
Portal Vein Tumor Thrombus
Interventions
DRUG:
sorafenib; toripalimab
Sponsor
Sichuan University